MapLight Therapeutics/$MPLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MapLight Therapeutics
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Ticker
$MPLT
Sector
Primary listing
Employees
133
Headquarters
Website
MPLT Metrics
BasicAdvanced
$1.4bn
-
-$18.56
-
-
Price and volume
Market cap
$1.4bn
52-week high
$33.28
52-week low
$12.24
Average daily volume
321k
Financial strength
Current ratio
20.006
Quick ratio
18.8
Long term debt to equity
1.071
Total debt to equity
1.266
Profitability
EBITDA (TTM)
-168.505
Management effectiveness
Return on assets (TTM)
-34.29%
Return on equity (TTM)
-56.19%
Valuation
Price to book
3.06
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
-1.996
Free cash flow yield (TTM)
-50.10%
Free cash flow per share (TTM)
-15.968
Growth
Earnings per share change (TTM)
-82.38%
3-year earnings per share growth (CAGR)
-29.90%
What the Analysts think about MPLT
Analyst ratings (Buy, Hold, Sell) for MapLight Therapeutics stock.
MPLT Financial Performance
Revenues and expenses
MPLT Earnings Performance
Company profitability
MPLT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MapLight Therapeutics stock?
MapLight Therapeutics (MPLT) has a market cap of $1.4B as of May 01, 2026.
What is the P/E ratio for MapLight Therapeutics stock?
The price to earnings (P/E) ratio for MapLight Therapeutics (MPLT) stock is 0 as of May 01, 2026.
Does MapLight Therapeutics stock pay dividends?
No, MapLight Therapeutics (MPLT) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next MapLight Therapeutics dividend payment date?
MapLight Therapeutics (MPLT) stock does not pay dividends to its shareholders.
What is the beta indicator for MapLight Therapeutics?
MapLight Therapeutics (MPLT) does not currently have a Beta indicator.